Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition.

Apoptosis : an international journal on programmed cell death - 1 Dec 2024

Pervushin N V, Nilov D K, Pushkarev S V, Shipunova V O, Badlaeva A S, Yapryntseva M A, Kopytova D V, Zhivotovsky B, Kopeina G S

Abstract excerpt

The development of drug resistance reduces the efficacy of cancer therapy. Tumor cells can acquire resistance to MDM2 inhibitors, which are currently under clinical evaluation. We generated RG7388-resistant neuroblastoma cells, which became more proliferative and metabolically active and were less sensitive to DNA-damaging agents in vitro and in vivo, compared with wild-type cells. The resistance was associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cisplatin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Damage

Share to Drug Resistance, Neoplasm

Share to Neuroblastoma

Share to Proto-Oncogene Proteins c-mdm2

Share to Pyrrolidines

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 39222276
DOI: 10.1007/s10495-024-02014-8
PMCID: PMC11550243

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition.PMID 39222276Read ↗

Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastomaSemantic proximity Read ↗

p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3.Semantic proximity Read ↗

Small-Molecule MDM2 Antagonists as a New Therapy Concept for NeuroblastomaSemantic proximity Read ↗

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?Semantic proximity Read ↗

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.Semantic proximity Read ↗

Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor TrametinibSemantic proximity Read ↗

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.Semantic proximity Read ↗

Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma CellsSemantic proximity Read ↗

Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.Semantic proximity Read ↗

Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3Semantic proximity Read ↗

Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis.Semantic proximity Read ↗

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical DevelopmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.